Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.

Company profile
Ticker
BSX
Exchange
Website
CEO
Michael Mahoney
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Acurate Industria e Comercio Ltda. • American Medical Systems Europe B.V. • Baylis Medical UK Limited • BAYLIS Medical (Deutschland) GmbH • Baylis Medical Company Inc. • Baylis Medical France S.A.R.L. • Baylis Medical USA Inc. • Biocompatibles UK Limited • Biocompatibles, Inc. • Boston Scientific (Malaysia) Sdn. Bhd. ...
IRS number
42695240
BSX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Boston Scientific Announces Results for Second Quarter 2023
27 Jul 23
8-K
Departure of Directors or Certain Officers
27 Jun 23
8-K
Other Events
6 Jun 23
25-NSE
Exchange delisting
1 Jun 23
SD
Conflict minerals disclosure
25 May 23
8-K
Submission of Matters to a Vote of Security Holders
9 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Boston Scientific Announces Results for First Quarter 2023
26 Apr 23
DEFR14A
Revised proxy
22 Mar 23
Transcripts
BSX
Earnings call transcript
2023 Q2
27 Jul 23
BSX
Earnings call transcript
2022 Q4
1 Feb 23
BSX
Earnings call transcript
2022 Q3
26 Oct 22
BSX
Earnings call transcript
2022 Q2
27 Jul 22
BSX
Earnings call transcript
2022 Q1
27 Apr 22
BSX
Earnings call transcript
2021 Q4
2 Feb 22
BSX
Earnings call transcript
2021 Q3
27 Oct 21
BSX
Earnings call transcript
2021 Q2
27 Jul 21
BSX
Earnings call transcript
2021 Q1
28 Apr 21
BSX
Earnings call transcript
2020 Q4
3 Feb 21
Latest ownership filings
4
Joseph Michael Fitzgerald
21 Sep 23
144
Notice of proposed sale of securities
20 Sep 23
4
Wendy Carruthers
15 Sep 23
144
Notice of proposed sale of securities
15 Sep 23
4
Michael F Mahoney
12 Sep 23
144
Notice of proposed sale of securities
12 Sep 23
4
Michael F Mahoney
1 Sep 23
4
Jeffrey B. Mirviss
30 Aug 23
144
Notice of proposed sale of securities
29 Aug 23
144
Notice of proposed sale of securities
28 Aug 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 620.00 mm | 620.00 mm | 620.00 mm | 620.00 mm | 620.00 mm | 620.00 mm |
Cash burn (monthly) | 47.67 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 140.04 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 479.96 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 10.1 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q2 2023
89.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1008 |
Opened positions | 130 |
Closed positions | 84 |
Increased positions | 380 |
Reduced positions | 340 |
13F shares | Current |
---|---|
Total value | 69.89 tn |
Total shares | 1.30 bn |
Total puts | 4.99 mm |
Total calls | 4.55 mm |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 137.49 mm | $7.44 tn |
Vanguard | 122.24 mm | $6.61 tn |
FMR | 117.88 mm | $6.38 tn |
Massachusetts Financial Services | 69.14 mm | $3.74 tn |
STT State Street | 63.19 mm | $3.42 tn |
Wellington Management | 39.74 mm | $2.15 tn |
Primecap Management | 37.43 mm | $2.02 tn |
BAC Bank Of America | 26.59 mm | $1.44 tn |
Geode Capital Management | 26.05 mm | $1.40 tn |
Bollard | 23.68 mm | $1.28 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Sep 23 | Joseph Michael Fitzgerald | Common Stock | Sell | Dispose S | No | Yes | 55 | 15,867 | 872.69 k | 197,992 |
15 Sep 23 | Wendy Carruthers | Common Stock | Sell | Dispose S | No | Yes | 53.9537 | 11,671 | 629.69 k | 57,058 |
15 Sep 23 | Wendy Carruthers | Common Stock | Option exercise | Acquire M | No | Yes | 13.08 | 2,960 | 38.72 k | 68,729 |
15 Sep 23 | Wendy Carruthers | Common Stock | Option exercise | Acquire M | No | Yes | 16.31 | 3,448 | 56.24 k | 65,769 |
15 Sep 23 | Wendy Carruthers | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 13.08 | 2,960 | 38.72 k | 8,879 |
15 Sep 23 | Wendy Carruthers | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 16.31 | 3,448 | 56.24 k | 10,346 |
12 Sep 23 | Michael F Mahoney | Common Stock | Sell | Dispose S | No | Yes | 53.9054 | 113,355 | 6.11 mm | 1,498,922 |
12 Sep 23 | Michael F Mahoney | Common Stock | Option exercise | Acquire M | No | Yes | 16.31 | 55,675 | 908.06 k | 1,612,277 |
12 Sep 23 | Michael F Mahoney | Common Stock | Option exercise | Acquire M | No | Yes | 13.08 | 57,680 | 754.45 k | 1,556,602 |
12 Sep 23 | Michael F Mahoney | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 13.08 | 57,680 | 754.45 k | 115,361 |
News
Here's How Much $100 Invested In Boston Scientific 15 Years Ago Would Be Worth Today
27 Sep 23
Jim Cramer Says 'Entertainment Stocks Are So Hated': Here's One That's 'Not Expensive Anymore'
27 Sep 23
Barclays Maintains Overweight on Boston Scientific, Raises Price Target to $60
22 Sep 23
Zoom Video, eBay And 2 Other Stocks Insiders Are Selling
22 Sep 23
Boston Scientific's 'Next Level' Long-Term Plans: Why 2 Analysts Boost Price Targets
21 Sep 23
Press releases
NeurAxis Stock Has 236% Upside Says GSCR Analyst, Fueled By Drug-Free IB-Stim Technology To Treat Pediatric Irritable Bowel Syndrome ($NRXS)
26 Sep 23
Analyst Models NeurAxis 12-Month Share Price Target At $14, 301% Higher Than Current Price ($NRXS)
21 Sep 23
CVS Health appoints Michael F. Mahoney to its Board of Directors
21 Sep 23
Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.
19 Sep 23
With Only 1.21 Million In The Trading Float, NeurAxis Stock Volatility Exposes An Opportunity, Not A Deterrent ($NRXS)
19 Sep 23